Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease

PLoS Medicine

Volumn 2, Issue 12, 2005, Pages 1292-1298

  Stafford, Randall S ^a   Monti, Veronica ^a   Ma, Jun ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TICLOPIDINE;

ADULT; AGE DISTRIBUTION; AGED; AMBULATORY CARE; ARTICLE; CARDIOLOGIST; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONSENSUS; CONSULTATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG USE; FEMALE; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; MALE; MEDICAL CARE; OUTPATIENT; PATIENT CARE; PATIENT COMPLIANCE; PHYSICIAN; PRACTICE GUIDELINE; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; UNITED STATES; CLINICAL PRACTICE; HEALTH CARE SURVEY; MIDDLE AGED; RISK ASSESSMENT; STANDARD; STATISTICS;

ADULT; AGED; AMBULATORY CARE; ASPIRIN; CARDIOVASCULAR DISEASES; FEMALE; HEALTH CARE SURVEYS; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RISK ASSESSMENT; UNITED STATES;

EID: 29644436413     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0020353     Document Type: Article

References (45)

1. Berg AO, Atkins D (2002) Aspirin for the primary prevention of cardiovascular events. US Preventive Services Task Force. Ann Intern Med 136: 157-160.
2. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, et al. (2002) AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 106: 388-391.
3. Hansson L, Zanchetti A, Carruthers S, Dahlof B, Elmfeldt D, et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 351: 1755-1762.
4. Steering Committee for the Physician's Health Study Research Group (1989) Final report on the aspirin component of the ongoing Physician's Health Study. The Steering Committee for the Physician's Health Study Research Group. N Engl J Med 321: 129-135.
5. Medical Research Council's General Practice Research Framework (1998) Thrombosis prevention trial: Randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 351: 233-241.
6. Collaborative Group of the Primary Prevention Project (2001) Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomized trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 357: 89-95.
7. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. (2005) A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352: 1293-1304.
8. ISIS-2 Collaborative Group (1988) Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2: Second International Study of Infarct Survival, Collaborative Group. Lancet 2: 349-360.
9. Anti-Platelet Trialists' Collaboration (2002) Collaborative meta-analysis of randomized trials of anti platelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients: Anti-Platelet Trialists' Collaboration. Br Med J 324: 71-86.
10. Weisman SM, Graham DY (2002) Evaluation of the bene.ts and risks of lowdose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 162: 2197-2202.
11. Chen Z, Sandercock P, Pan H, Counsell C, Collins R, et al. (2000) Indications for early aspirin use in acute ischemic stroke. A combined analysis of 40,000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. Stroke 31: 1240-1249.
12. Harrington RA, Becker RC, Ezekowitz M, Meade TW, O'Connor CM, et al. (2004) Antithrombotic therapy for coronary artery disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 513S-548S.
13. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P (2004) Antithrombotic and thrombolytic therapy for ischemic stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 483S-512S.
14. American Diabetes Association (2004) Aspirin therapy in diabetes. Diabetes Care 27: S72-S73.
15. Stafford RS, Radley DC (2003) The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol 41: 69-72.
16. Stafford RS (2000) Aspirin use is low among United States outpatients with coronary artery disease. Circulation 101: 1097-1101.
17. Rolka DB, Fagot-Campagna A, Narayan KM (2001) Aspirin use among adults with diabetes. Estimates from the Third National Health and Nutrition Examination Survey. Diabetes Care 24: 197-201.
18. Kramer JM, Newby LK, Chang WC, Simes RJ, Van de Werf F, et al. (2003) International variation in the use of evidence based medicines for acute coronary syndromes. Eur Heart J 24: 2133-2141.
19. Venturini F, Romero M, Tognoni G, (1999) Patterns of practice for acute myocardial infarction in a population from ten countries. Eur J Clin Pharmacol 54: 877-886.
20. O'Connor GT, Quinton HB, Traven ND, Ramunno LD, Dodds TA, et al. (1999) Geographic variation in the treatment of acute myocardial infarction: The Cooperative Cardiovascular Project. JAMA 281: 627-633.
21. Bennett KE, Williams D, Feely J (2003) Under-prescribing of cardiovascular therapies for diabetes in primary care. Eur J Clin Pharmacol 58: 835-841.
22. EUROASPIRE II (2001) Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: Principal results from EUROASPIRE II Euro Heart Survey Programme. EUROASPIRE II Study Group. Eur Heart J 22: 526-528.
23. Steffenino G, Galliasso M, Gastaldi C, Ricca N, Mangiacotti B (2003) Nurses' observational study on the practice of secondary prevention in a cardiovascular department. Ital Heart J 4: 473-478.
24. Avezum A, Makdisse M, Spencer F, Gore JM, Fox KAA, et al. (2005) Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 149: 67-73.
25. Meigs JB, Stafford RS (2000) Cardiovascular disease prevention practices by U.S. physicians for patients with diabetes. J Gen Intern Med 15: 220-228.
26. Califf RM, DeLong ER, Ostbye T, Muhlbaier LH, Chen A, et al. (2002) Underuse of aspirin in a referral population with documented coronary artery disease. Am J Cardiol 89: 653-661.
27. Ganz DA, Lamas GA, Orav EJ, Goldman L, Gutierrez PR, et al. (1999) Age related differences in management of heart disease: A study of cardiac medication use in an older cohort. Pacemaker Selection in the Elderly (PASE) Investigators. J Am Geriat Soc 47: 145-150.
28. Krumholz HM, Radford MJ, Ellerbeck EF, Hennen J, Meehan TP, et al. (1995) Aspirin in the treatment of acute myocardial infarction in elderly Medicare bene.ciaries. Patterns of use and outcomes. Circulation 92: 2841-2847.
29. Zell ER, McCaig LF, Kupronis BA, Besser RE, Schuchat A (2000) A comparison of the National Disease and Therapeutic Index and the National Ambulatory Medical Care Survey to evaluate antibiotic usage. In: Proceedings of the survey research methods section, American Statistical Association. Alexandria (Virginia): American Statistical Association. pp. 840-845
30. Gilchrist VJ, Stange KC, Flocke SA, McCord G, Bourguet CC (2004) A comparison of the National Ambulatory Medical Care Survey (NAMCS) measurement approach with direct observation of outpatient visits. Medical Care 42: 276-280.
31. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, et al. (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97: 1837-1847.
32. Colwell JA (2001) Aspirin therapy in diabetes is underutilized. Diabetes Care 24: 194-196.
33. Devereaux PJ, Anderson DR, Gardner MJ, Putnam W, Flowerdew GJ, et al. (2001) Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: Observational study. Br Med J 323: 1218-1222.
34. Laine L (2002) The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Semin Arthritis Rheum 32: 25-32.
35. ETDRS (1992) Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14: ETDRS Investigators. JAMA 268: 1292-1300.
36. Short D, Frischer M, Bashford J, Ashcroft D (2003) Why are eligible patients not prescribed aspirin in primary care? A qualitative study indicating measures for improvement. BMC Fam Pract 4: 9.
37. Martin CP, Talbert HR (2005) Aspirin resistance: an evaluation of current evidence and measurement methods. Pharmacotherapy 25: 942-953.
38. Lee PY, Chen WH, Ng W, Cheng X, Kwok JY, et al. (2005) Low-dose aspirin increases resistance in patients with coronary artery disease. Am J Med 118: 723-727.
39. Marshall T (2003) Coronary heart disease prevention: Insights from modelling incremental cost effectiveness. Br Med J 327: 1-5.
40. Drummond A, Kwok S, Morgan J, Durrington PN (2001) Costs of aspirin and statins in general practice. QJM 95: 23-26.
41. Probstfield JF (2003) How cost-effective are new preventive strategies for cardiovascular disease? Am J Cardiol 91: 22G-27G.
42. Hennekens CH, Sacks FM, Tonkin A, Jukema JW, Byington RP, et al. (2004) Additive bene.ts of pravastatin and aspirin to decrease risks of cardiovascular disease. Arch Intern Med 164: 40-44.
43. Ma J, Stafford RS, Cockburn IM, Finkelstein SN (2003) A statistical analysis of the magnitude and composition of drug promotion in the United States in 1998. Clin Ther 25: 1503-1517.
44. Frances CD, Go AS, Dauterman KW, Deosaransingh K, Jung DL, et al. (1999) Outcome following acute myocardial infarction: Are differences among physician specialties the result of quality of care or case mix? Arch Intern Med 159: 1429-1436.
45. Akosah KO, Larson DE, Brown WM, Paul K, Schaper A, et al. (2003) Using a systemwide care path to enhance compliance with guidelines for acute myocardial infarction. Jt Comm J Qual Saf 29: 245-259.